As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated with ...

Alogliptin and Pioglitazone combination is used to treat high blood sugar level in patients with type 2 diabetes along with diet control and exercise. Regular exercise especially in type II diabetes ...

Takeda announced results from the EXAMINE study on cardiovascular safety following treatment with alogliptin in addition to standard of care in patients with type 2 diabetes (T2DM) and recent acute ...

Learn everything you need to know about Alogliptin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Pioglitazone, Bladder Cancer Risk: No Link in 10-Year Study Takeda announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the Food and Drug Administration (FDA) has met to ...

Please provide your email address to receive an email when new articles are posted on . Alogliptin monotherapy was well tolerated and improved glycemic control in patients with type 2 diabetes without ...

Alogliptin is an effective add-on to glimepiride therapy for improving glycemic control in Japanese patients with Type 2 diabetes, show study findings. Furthermore, the benefits of the combination ...

San Francisco, Calif., June 07, 2008 – Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association (ADA) 68th Scientific Sessions by Takeda Global ...

Takeda Pharmaceutical Co is going to have to wait a bit longer to market alogliptin after US regulators said they need more time to evaluate the Japanese drugmaker’s experimental type 2 diabetes drug.

Please provide your email address to receive an email when new articles are posted on . AMSTERDAM — In patients with type 2 diabetes and recent ACS, major adverse CV event rates were not increased ...

Takeda Pharmaceutical Co faces a delay in getting alogliptin to market after US regulators said that they need more data to evaluate the Japanese drugmaker’s experimental type 2 diabetes drug. Takeda ...

In agreement with a previous meta-analysis, that was conducted on DPP-4 inhibitors including four studies on alogliptin, [27] this meta-analysis has demonstrated a significant reduction of HbA1c and ...